Evaluation of Non-Supervised MALDI Mass Spectrometry Imaging Combined to MicroProteomics for Glioma Grade III Classification

ABSTRACT: An integrated diagnosis using molecular features is recommended in the updated World Health Organization (WHO) classification. Our aim was to explore the role of MALDI-Mass spectrometry imaging (MSI) coupled to microproteomics in order to classify anaplastic glioma by integration of clinical data.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain

DISEASE(S): Brain Cancer

SUBMITTER: Maxence Wisztorski  

LAB HEAD: Michel Salzet

PROVIDER: PXD004437 | Pride | 2016-12-13

REPOSITORIES: Pride